# WIA-BIO-002: Security & Privacy Specification

## Version 1.0 | 2025-01-15

---

## Table of Contents
1. [Overview](#overview)
2. [Patient Data Protection](#patient-data-protection)
3. [Vector Design IP Protection](#vector-design-ip-protection)
4. [Manufacturing Data Security](#manufacturing-data-security)
5. [Clinical Trial Privacy](#clinical-trial-privacy)
6. [Germline Modification Ethics](#germline-modification-ethics)
7. [Long-Term Follow-Up Privacy](#long-term-follow-up-privacy)

---

## Overview

Gene therapy raises unique privacy challenges beyond standard PHI protection: germline transmission implications, familial genetic information disclosure, long-term surveillance requirements (up to 15 years per FDA), and proprietary vector design protection. WIA-BIO-002 mandates comprehensive safeguards addressing both patient privacy and intellectual property.

### Unique Privacy Risks

| Risk Category | Description | Mitigation |
|---------------|-------------|------------|
| **Germline Implications** | Genetic modifications may affect offspring | Informed consent, contraception requirements, pregnancy registries |
| **Familial Information** | Treatment reveals family disease genetics | De-identified family history, genetic counseling |
| **15-Year LTFU** | Mandatory FDA long-term follow-up | Consent for extended surveillance, data minimization |
| **Shedding Monitoring** | Vector shedding data from bodily fluids | Secure handling of biological specimens |
| **Integration Site Data** | Reveals unique genomic fingerprint | Controlled access, encryption of IS data |

---

## Patient Data Protection

### Informed Consent Requirements

**Gene Therapy-Specific Elements (21 CFR 50.25):**

```
1. Vector Description
   - Type (AAV, lentivirus, etc.)
   - Mechanism of action
   - Permanent vs. transient expression

2. Risks Specific to Gene Therapy
   - Insertional mutagenesis (integrating vectors)
   - Immune responses (anti-capsid, anti-transgene)
   - Potential germline transmission
   - Unknown long-term risks
   - Possibility of irreversibility

3. Alternative Treatments
   - Standard of care options
   - Other investigational therapies

4. Long-Term Follow-Up Obligations
   - Duration: Up to 15 years
   - Frequency of visits and tests
   - Biological sample collection
   - Contact if patient moves/changes providers

5. Reproductive Considerations
   - Contraception requirement (typically 6-12 months)
   - Partner notification if exposure occurs
   - Pregnancy registry enrollment
   - Sperm/ova banking options (if fertility affected)

6. Data Sharing
   - De-identified data may be shared with sponsors, FDA, researchers
   - Integration site data (if applicable)
   - Right to withdraw (with limitations post-treatment)

7. Genetic Information Disclosure
   - May reveal information about biological relatives
   - Family members may be contacted for safety surveillance
```

**Dynamic Consent Platform:**
```json
{
  "consentId": "GT_CONSENT_001",
  "patientId": "PATIENT_001_DEIDENTIFIED",
  "initialDate": "2025-01-10",
  "status": "active",
  "permissions": {
    "treatment": true,
    "dataSharing": {
      "sponsor": true,
      "regulators": true,
      "academicResearch": false,
      "commercial": false
    },
    "biologicalSamples": {
      "storage": true,
      "futureResearch": false,
      "geneticTesting": true
    },
    "familyContact": {
      "adverseEvents": true,
      "newFindings": true
    },
    "longTermFollowUp": {
      "duration": "15 years",
      "contactMethods": ["email", "phone", "mail"]
    }
  },
  "updates": [
    {
      "date": "2025-03-15",
      "change": "Withdrew commercial data sharing consent",
      "reason": "Patient preference"
    }
  ]
}
```

---

### De-identification Standards

**HIPAA Safe Harbor + Gene Therapy Additions:**

```
Standard 18 HIPAA Identifiers to Remove:
1. Names
2. Geographic subdivisions <state
3. All dates (except year of treatment)
4. Telephone/fax numbers
5. Email addresses
6. SSN
7. Medical record numbers
8. Health plan beneficiary numbers
9. Account numbers
10. Certificate/license numbers
11. Vehicle identifiers
12. Device identifiers
13. URLs
14. IP addresses
15. Biometric identifiers
16. Full-face photos
17. Unique identifying numbers
18. Genomic sequences (with caveats)

Gene Therapy-Specific Additions:
19. Vector lot numbers (if traceable to individual)
20. Exact integration site coordinates (replace with region)
21. Rare variant combinations
22. Unique adverse event timelines
23. Institutional identifiers for single-patient sites
```

**Re-identification Risk Assessment:**
```python
def assess_reidentification_risk(patient_data):
    """
    Assess re-identification risk for gene therapy patient data
    """
    risk_score = 0

    # Check for rare disease (small population)
    if patient_data['disease_prevalence'] < 1/100000:
        risk_score += 3  # High risk: small patient population

    # Check for unique integration sites
    if 'integration_sites' in patient_data:
        unique_sites = count_unique_sites(patient_data['integration_sites'])
        if unique_sites > 10:
            risk_score += 4  # Very high: genomic fingerprint

    # Check for rare adverse events
    if patient_data.get('adverse_events'):
        if any(ae['rarity'] == 'unique' for ae in patient_data['adverse_events']):
            risk_score += 2

    # Geographic granularity
    if patient_data.get('location_detail', 'state') == 'city':
        risk_score += 1

    # Mitigation recommendations
    if risk_score >= 5:
        return {
            'risk': 'HIGH',
            'recommendation': 'Apply differential privacy, suppress rare events, generalize geographic data'
        }
    elif risk_score >= 3:
        return {
            'risk': 'MODERATE',
            'recommendation': 'Aggregate small cells (n<5), remove exact dates'
        }
    else:
        return {
            'risk': 'LOW',
            'recommendation': 'Standard de-identification sufficient'
        }
```

---

## Vector Design IP Protection

### Proprietary Sequence Protection

**Trade Secret Safeguards:**

```
1. Plasmid Sequences
   - Redact proprietary elements in regulatory submissions
   - Provide sequence to FDA in secure, non-public Module 3.2.S
   - Mark as "Confidential Commercial Information" (CCI)

2. Capsid Engineering
   - Patent novel AAV variants (e.g., AAV-PHP.B)
   - Maintain lab notebooks with witnessed entries
   - Secure computational design files

3. Manufacturing Process
   - Document as trade secret (not patented)
   - Restrict access to essential personnel only
   - Non-disclosure agreements for vendors

4. CMC Data Security
   - Encrypted transmission to regulatory agencies
   - Watermark critical documents
   - Track document access in LIMS
```

**GenBank Submission Redaction:**
```genbank
LOCUS       AAV_PROPRIETARY_VECTOR  4679 bp    DNA     circular SYN 15-JAN-2025
DEFINITION  AAV vector with proprietary capsid and regulatory elements [CCI REDACTED]
...
FEATURES             Location/Qualifiers
     promoter        612..1211
                     /label=[CONFIDENTIAL COMMERCIAL INFORMATION]
                     /note="Proprietary tissue-specific promoter"
     CDS             1235..1954
                     /label=Therapeutic_Transgene
                     /codon_start=1
                     /note="Sequence available to FDA under protective order"
                     /translation="REDACTED"
```

---

### Clinical Trial Registry Disclosure

**ClinicalTrials.gov Required Elements:**

```xml
<ProtocolSection>
  <InterventionName>AAV9-[PROPRIETARY_NAME]</InterventionName>
  <InterventionType>Genetic</InterventionType>
  <InterventionDescription>
    Adeno-associated virus serotype 9 vector delivering [GENE_NAME]
    under control of [PUBLIC_PROMOTER or "proprietary promoter"].
    <!-- Do NOT disclose: exact sequence, capsid mutations, formulation details -->
  </InterventionDescription>
  <ArmGroup>
    <ArmGroupLabel>Gene Therapy</ArmGroupLabel>
    <ArmGroupInterventionName>AAV9-[NAME]</ArmGroupInterventionName>
    <ArmGroupDescription>
      Single IV infusion of 1.1×10^14 vg/kg (weight-based dosing)
      <!-- Exact concentration and formulation buffer: REDACTED as CCI -->
    </ArmGroupDescription>
  </ArmGroup>
</ProtocolSection>
```

---

## Manufacturing Data Security

### GMP Facility Access Control

**Tiered Access Model:**

| Role | Access Level | Permitted Areas | Data Access |
|------|--------------|-----------------|-------------|
| **QA Manager** | Level 5 | All areas | Full batch records, deviations |
| **Manufacturing Associate** | Level 3 | Production suites only | SOPs, batch sheets (assigned batches) |
| **QC Analyst** | Level 4 | QC lab, data review room | Test methods, results, COAs |
| **Maintenance** | Level 2 | Equipment rooms (escorted) | Equipment manuals only |
| **Visitors** | Level 1 | Viewing corridors | None |

**Electronic Batch Record (EBR) Audit Trail:**
```json
{
  "batchId": "AAV9-001",
  "auditTrail": [
    {
      "timestamp": "2025-01-15T08:05:23Z",
      "user": "OPERATOR_001",
      "action": "RECORD_CREATED",
      "field": "Batch Record",
      "oldValue": null,
      "newValue": "New batch initiated",
      "ipAddress": "10.5.2.45",
      "workstation": "MFG_SUITE_A_WS01"
    },
    {
      "timestamp": "2025-01-15T09:15:42Z",
      "user": "OPERATOR_001",
      "action": "FIELD_UPDATED",
      "field": "Transfection_Start_Time",
      "oldValue": null,
      "newValue": "2025-01-15T09:15:00Z",
      "electronicSignature": "OPERATOR_001_SIG_20250115091542",
      "reason": "Actual transfection time recorded"
    },
    {
      "timestamp": "2025-01-23T10:30:15Z",
      "user": "QA_MANAGER_001",
      "action": "BATCH_APPROVED",
      "field": "Disposition",
      "oldValue": "Pending QA Review",
      "newValue": "RELEASED",
      "electronicSignature": "QA_MGR_SIG_20250123103015",
      "reason": "All QC tests passed, batch released for clinical use"
    }
  ]
}
```

**21 CFR Part 11 Compliance:**
```
Electronic Signature Requirements:
1. Unique user ID + password (minimum 12 characters)
2. Two-factor authentication for critical records
3. Audit trail captures: who, what, when, why
4. Electronic signatures legally binding (equivalent to handwritten)
5. System validates user at time of signature
6. No shared logins

Record Integrity:
- Hash-based checksums (SHA-256) for all records
- Immutable audit trails (append-only)
- Backup every 24 hours, offsite weekly
- Retention: 3 years after BLA approval or 10 years (whichever longer)
```

---

## Clinical Trial Privacy

### Adverse Event Reporting (De-identified)

**MedWatch Form 3500A (FDA):**
```
Patient Identifier: STUDY_001_SUBJ_042 (NOT patient name/SSN)
Age: 5 (years, months if <2 years old)
Sex: M
Weight: 8.5 kg

Event Description:
[REDACTED: Remove hospital name, physician name, exact dates beyond month/year]

"5-year-old male enrolled in AAV9-hSMN1 trial experienced transaminitis
(ALT 285 U/L) 3 weeks post-infusion. Managed with prednisone 1 mg/kg PO daily.
ALT normalized within 4 weeks. Transgene expression maintained. No sequelae."

Causality Assessment: Probably Related
Outcome: Recovered
Reporter: INVESTIGATOR_001 [Medical degree, institutional affiliation REDACTED]
```

**SAE (Serious Adverse Event) Narrative Redaction:**
```
BEFORE (Identified):
"On January 15, 2025, John Doe, a 5-year-old boy from Boston Children's Hospital
(MRN 12345678), treated by Dr. Jane Smith, developed..."

AFTER (De-identified):
"Approximately [TIME_REDACTED] weeks post-infusion, a 5-year-old male enrolled at
Site 03 developed..."
```

---

### Integration Site Data Protection

**Genomic Privacy for IS Analysis:**

```python
# Integration site anonymization
def anonymize_integration_sites(is_data, precision='100kb'):
    """
    Reduce integration site precision to prevent genomic fingerprinting
    """
    anonymized = []
    for site in is_data:
        # Round position to nearest 100kb
        rounded_pos = round(site['position'] / 100000) * 100000

        anonymized_site = {
            'chr': site['chr'],
            'position_range': f"{rounded_pos}-{rounded_pos + 100000}",  # Range, not exact
            'gene_nearby': site['gene'],  # Keep gene context
            'abundance_bin': bin_abundance(site['abundance']),  # Binned, not exact %
            'patient': hash_patient_id(site['patient'])  # One-way hash
        }
        anonymized.append(anonymized_site)

    return anonymized

def bin_abundance(abundance_pct):
    """Bin clonal abundance to prevent unique identification"""
    if abundance_pct < 0.1:
        return "<0.1%"
    elif abundance_pct < 1:
        return "0.1-1%"
    elif abundance_pct < 5:
        return "1-5%"
    elif abundance_pct < 10:
        return "5-10%"
    else:
        return f">{int(abundance_pct)}%" # Round to integer for high clones
```

**Controlled Access Tiers:**

| Data Type | Access Tier | Authorized Users | Purpose |
|-----------|-------------|------------------|---------|
| **Aggregated IS** | Public | Anyone | Population-level research |
| **Regional IS** (100kb bins) | Registered | Approved researchers with DUA | Gene-level analysis |
| **Exact IS coordinates** | Controlled | Sponsor, FDA, IRB only | Safety surveillance |
| **Patient-linked IS** | Highly Restricted | Treating physician only | Clinical care |

---

## Germline Modification Ethics

### Regulatory Prohibitions (Current Status)

**Global Landscape:**

| Region | Germline Gene Editing | Somatic Gene Therapy | Regulatory Body |
|--------|----------------------|---------------------|-----------------|
| **United States** | PROHIBITED (no federal funding) | PERMITTED | FDA, NIH RAC |
| **European Union** | PROHIBITED (Directive 2001/18/EC) | PERMITTED | EMA |
| **China** | TECHNICALLY PROHIBITED (post-He Jiankui) | PERMITTED | NMPA |
| **Japan** | PROHIBITED | PERMITTED | MHLW |
| **United Kingdom** | RESEARCH ONLY (no implantation) | PERMITTED | MHRA |

**WIA-BIO-002 Position:**
```
Gene therapy vectors MUST NOT be designed for or used in:
1. Modification of human germline (eggs, sperm, embryos)
2. Enhancement of non-disease traits
3. Heritable genetic modifications (intentional)

Required Safeguards:
- Contraception for 6-12 months post-treatment (vector-dependent)
- Pregnancy testing before treatment (females of childbearing potential)
- Semen analysis for vector shedding (males)
- Partner notification and consent if conception occurs during contraception period
- Pregnancy registry enrollment for all exposed pregnancies
```

---

### Inadvertent Germline Exposure Protocol

**If Patient Becomes Pregnant During Contraception Period:**

```
1. Immediate Notification
   - Patient informs investigator within 24 hours
   - Investigator notifies IRB and sponsor within 24 hours
   - FDA MedWatch report within 15 calendar days

2. Genetic Counseling
   - Explain theoretical risks (no human data)
   - Present preclinical animal data
   - Discuss options: continue pregnancy, terminate, adoption

3. Monitoring (If Pregnancy Continues)
   - Enroll in Pregnancy Exposure Registry
   - Amniocentesis at 16-20 weeks (optional, patient choice)
     - Vector genome qPCR in amniotic fluid
     - Karyotype analysis
   - High-resolution ultrasound at 18-20 weeks
   - Neonatal assessment at birth

4. Neonatal Follow-Up
   - Cord blood vector genome analysis
   - Peripheral blood vector genome at 1, 6, 12 months
   - Developmental milestones tracking
   - Genome sequencing at 1 year (if vector detected)

5. Long-Term Registry
   - Annual health surveys for 18 years
   - Consent for future contact if new data emerges
```

---

## Long-Term Follow-Up Privacy

### FDA LTFU Guidance (15-Year Surveillance)

**Retention and Contact Requirements:**

```json
{
  "ltfuProtocol": {
    "duration": "15 years post-treatment",
    "schedule": {
      "year1": "Quarterly visits",
      "year2_5": "Biannual visits",
      "year6_15": "Annual visits + phone contact"
    },
    "assessments": [
      {
        "test": "Transgene expression",
        "frequency": "All visits",
        "method": "Protein ELISA or functional assay"
      },
      {
        "test": "Integration site analysis",
        "frequency": "Years 1, 3, 5, 10, 15",
        "method": "LAM-PCR + NGS",
        "privacy": "Controlled access, de-identified"
      },
      {
        "test": "New malignancies",
        "frequency": "All visits",
        "method": "Clinical exam, patient report, cancer registry linkage"
      }
    ],
    "contactMaintenance": {
      "methods": ["phone", "email", "mail", "patient portal"],
      "updateFrequency": "Annual",
      "lostToFollowUp": {
        "attempts": "3 calls, 2 mails, 1 certified mail",
        "interval": "Monthly for 3 months",
        "finalAttempt": "Private investigator or national death index search"
      }
    },
    "dataRetention": {
      "identifiedData": "Maintained by sponsor for LTFU duration + 10 years",
      "deidentifiedData": "May be retained indefinitely for research"
    }
  }
}
```

**Privacy Risks of Extended Surveillance:**

| Risk | Description | Mitigation |
|------|-------------|------------|
| **Data Breach Over Time** | 15 years = high cumulative risk | Encrypt all data, key rotation annually |
| **Vendor Changes** | CROs may merge/dissolve | Data ownership clauses, migration plans |
| **Patient Moves** | Address changes over 15 years | Multiple contact methods, emergency contacts |
| **Deceased Patients** | Death does not end LTFU (autopsy data) | Next-of-kin consent, autopsy protocols |
| **Sponsor Bankruptcy** | Company may cease to exist | FDA requires LTFU transfer plan in BLA |

---

### Data Minimization for LTFU

**Collect Only Essential Data:**

```
NECESSARY:
- Transgene expression levels
- New malignancies or hospitalizations
- Integration site clonality (integrating vectors)
- Vital status (alive/deceased)
- Pregnancy outcomes (if applicable)

NOT NECESSARY (Minimize Collection):
- Detailed lifestyle data (unless directly related to therapy)
- Full medical records (only gene therapy-relevant)
- Continuous GPS tracking
- Social media monitoring

Rationale: Balance safety surveillance with patient privacy burden
```

---

**Document Version:** 1.0
**Last Updated:** 2025-01-15
**Maintained by:** WIA BIO Working Group
**License:** Apache 2.0
